Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management
Hesham Abboud,John Probasco,Sarosh R Irani,Beau Ances,David R Benavides,Michael Bradshaw,Paulo Pereira Christo,Russell C Dale,Mireya Fernandez-Fournier,Eoin P Flanagan,Avi Gadoth,Pravin George,Elena Grebenciucova,Adham Jammoul,Soon-Tae Lee,Yuebing Li,Marcelo Matiello,Anne Marie Morse,Alexander Rae-Grant,Galeno Rojas,Ian Rossman,Sarah Schmitt,Arun Venkatesan,Steven Vernino,Sean J Pittock,Maarten Titulaer,Autoimmune Encephalitis Alliance Clinicians Network,Rawan Tarawneh,Heather Van Mater,Eyal Muscal,Ilene Ruhoy,Yaacov Anziska,Erin Longbrake,Susa Benseler,Cynthia Wang,Michelle Apperson,Raffaele Iorio,Mateus Mistieri Simabukuro,Ning Zhong,Stephan Rüegg,Amanda Piquet,Jonathan Kuo,Bahadir Konuskan,Elena Frid,Joseph Deng,Wendy Mitchell,GenaLynne Mooneyham,Riwanti Estiasari,Yuhei Chiba,Melanie Alarcio,Velda Han,Jon P Williams,Michael Sweeney,Tania Cellucci,Kyle Blackburn,Marisa Klein-Gitelman,Jonathan Santoro,Raymond Suarez,Jose Irazuzta,Staley Brod,Ann Hyslop,Katrina Irene Manibog,Domingo Escudero,William Horace Noland,Stacey Clardy,Soe Mar,William Kilgo
DOI: https://doi.org/10.1136/jnnp-2020-325302
2021-03-01
Abstract:The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune encephalitis as a broad category rather than focusing on individual antibody syndromes. Core authors from the Autoimmune Encephalitis Alliance Clinicians Network reviewed literature and developed the first draft. Where evidence was lacking or controversial, an electronic survey was distributed to all members to solicit individual responses. Sixty-eight members from 17 countries answered the survey. The most popular bridging therapy was oral prednisone taper chosen by 38% of responders while rituximab was the most popular maintenance therapy chosen by 46%. Most responders considered maintenance immunosuppression after a second relapse in patients with neuronal surface antibodies (70%) or seronegative autoimmune encephalitis (61%) as opposed to those with onconeuronal antibodies (29%). Most responders opted to cancer screening for 4 years in patients with neuronal surface antibodies (49%) or limbic encephalitis (46%) as opposed to non-limbic seronegative autoimmune encephalitis (36%). Detailed survey results are presented in the manuscript and a summary of the diagnostic and therapeutic recommendations is presented at the conclusion.